Miris Holding, a pioneering company in the field of human milk analysis, has announced a significant development in its expansion within the United States. Cedars-Sinai, a prestigious academic hospital known for its advanced neonatal care, has placed an order for a second Miris HMA® package. This decision underscores the clinical value of Miris' technology and points to an increasing market opportunity for the company.

In 2020, Cedars-Sinai became one of the first major hospitals to adopt the Miris HMA®, a state-of-the-art human milk analyzer designed to support neonatal care by providing critical insights into milk composition. The recent order for an additional unit not only highlights the hospital's satisfaction but also signals a broader trend in the healthcare sector where larger hospitals are recognizing the need for multiple systems to ensure analytical availability.

Marie Ekholm, Sales and Marketing Director at Miris, emphasized the strategic importance of this order: 'Cedars-Sinai's decision to install another Miris HMA confirms the clinical utility of human milk analysis in advanced neonatal care. For Miris, this indicates a larger addressable market, where larger hospitals practically require two systems per site. It strengthens our reference portfolio and drives an increase in recurring revenues over time.'

The order, valued at approximately 470,000 SEK, is expected to generate recurring annual revenues of about 40,000 SEK. This development not only enhances Miris' reference base in the US but also has the potential to accelerate new sales and scaling with existing customers.

From an investment perspective, this expansion into a key market like the US, particularly with a reputable institution such as Cedars-Sinai, positions Miris favorably for future growth. The increasing demand for their technology in neonatal care settings suggests a positive outlook for the company's revenue streams. Therefore, investors might consider this as a promising opportunity to buy and hold Miris shares as the company continues to strengthen its market position.